Evidence map›Paper›PMID 26543556›Full record

ArticleGigaScience2015

Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.

Michael Dean, Joseph Boland, Meredith Yeager, Kate M Im, Lisa Garland, Maria Rodriguez-Herrera, Mylen Perez, Jason Mitchell, David Roberson, Kristine Jones and 13 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in GigaScience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01251900 completednot on this map

BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2011Enrolled266ConditionsBreast Neoplasms
NCT03959267 nacompletednot on this mapstarted 2017, after this paper: background citation

Testing a Culturally Adapted Telephone Genetic Counseling Intervention to Enhance Genetic Risk Assessment in Underserved Latinas at Risk of Hereditary Breast and Ovarian Cancer

TypeinterventionalSponsorGeorgetown UniversityRan2017 to 2021Enrolled37ConditionsBreast Cancer, Hereditary Breast CancerArmsTelephone Genetic Counseling
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Circulating tumour DNA - looking beyond the blood.Nature reviews. Clinical oncology · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.Journal of racial and ethnic health disparities · 2019
    Review
  14. Review
  15. A RecurrentCancers · 2018
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Michael DeanLaboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Joseph BolandCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Meredith YeagerCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Kate M ImLaboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Lisa GarlandLaboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Maria Rodriguez-HerreraLaboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Mylen PerezLaboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702 USA.
Jason MitchellCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
David RobersonCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Kristine JonesCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Hyo Jung LeeCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Rebecca EggebeenCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Julie SawitzkeBasic Science Program, Leidos Biomedical Research, Inc., Frederick, MD USA.
Sara BassCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Xijun ZhangCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD USA.
Vivian RoblesNueva Vida Richmond, Richmond, VA USA.
Celia HollisLatino Community Development Agency, Oklahoma City, OK USA.
Claudia BarajasLatino Community Development Agency, Oklahoma City, OK USA.
Edna RathTexas Tech University Health Sciences Center, El Paso, TX USA.
Candy ArentzTexas Tech University Health Sciences Center, Lubbock, TX USA.
Jose A FigueroaTexas Tech University Health Sciences Center, Lubbock, TX USA.
Diane D NguyenTexas Tech University Health Sciences Center, Lubbock, TX USA.
Zeina NahlehTexas Tech University Health Sciences Center, El Paso, TX USA.
National Cancer Institute · USDivision of Cancer Epidemiology and GeneticsCancer Genetics (United States) · USTexas Tech University Health Sciences Center · USTexas Tech University · USLeidos (United States) · USNueva Vida · US

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundGermline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4-5 times less likely to receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 % HER2+, and 17 % had triple-negative disease.

resultsA total of seven different predicted deleterious mutations were identified, one newly described and the rest rare. In addition, four variants of unknown effect were found.

conclusionsApplication of this strategy on a larger scale could lead to improved cancer care of minority and underserved populations.

Indexed as

Genes, BRCA1Genes, BRCA2Breast NeoplasmsFemaleHispanic or LatinoHumansBreast cancerGenetic testingHealth disparityHispanic populationsUnderserved populations

Identifiers

PMID26543556
PMCPMC4634732
OpenAlexW2145225945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.